Diem Vuong

Zurich, ZH, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Corrigendum to "Robustness of radiomic features in magnetic resonance imaging for patients with glioblastoma: Multi-center study" [Phys. Imaging Radiat. Oncol. 22 (2022) 131-136].

Corrigendum to "Robustness of radiomic features in magnetic resonance imaging for patients with glioblastoma: Multi-center study" [Phys. Imaging Radiat. Oncol. 22 (2022) 131-136].

Journal: Physics and imaging in radiation oncology

Published: July 05, 2022

PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors.

PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors.

Journal: Frontiers in oncology

Published: June 24, 2022

Corrigendum to 'Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials': [ESMO Open Volume 7, Issue 2, (2022), 100455].

Corrigendum to 'Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials': [ESMO Open Volume 7, Issue 2, (2022), 100455].

Journal: ESMO open

Published: April 25, 2022

Improved Survival Prediction by Combining Radiological Imaging and S-100B Levels Into a Multivariate Model in Metastatic Melanoma Patients Treated With Immune Checkpoint Inhibition.

Improved Survival Prediction by Combining Radiological Imaging and S-100B Levels Into a Multivariate Model in Metastatic Melanoma Patients Treated With Immune Checkpoint Inhibition.

Journal: Frontiers in oncology

Published: December 07, 2021

Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials.

Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials.

Journal: ESMO open

Published: October 10, 2021

Robustness of radiomic features in magnetic resonance imaging for patients with glioblastoma: Multi-center study.

Robustness of radiomic features in magnetic resonance imaging for patients with glioblastoma: Multi-center study.

Journal: Physics and imaging in radiation oncology

Published: October 10, 2021

Systematic Review on the Association of Radiomics with Tumor Biological Endpoints.

Systematic Review on the Association of Radiomics with Tumor Biological Endpoints.

Journal: Cancers

Published: May 19, 2021

Quantification of the spatial distribution of primary tumors in the lung to develop new prognostic biomarkers for locally advanced NSCLC.

Quantification of the spatial distribution of primary tumors in the lung to develop new prognostic biomarkers for locally advanced NSCLC.

Journal: Scientific reports

Published: April 23, 2021

Preselection of robust radiomic features does not improve outcome modelling in non-small cell lung cancer based on clinical routine FDG-PET imaging.

Preselection of robust radiomic features does not improve outcome modelling in non-small cell lung cancer based on clinical routine FDG-PET imaging.

Journal: EJNMMI research

Published: March 19, 2021

Impact of CT convolution kernel on robustness of radiomic features for different lung diseases and tissue types.

Impact of CT convolution kernel on robustness of radiomic features for different lung diseases and tissue types.

Journal: The British journal of radiology

Published: February 05, 2021

Radiomic Analysis to Predict Outcome in Recurrent Glioblastoma Based on Multi-Center MR Imaging From the Prospective DIRECTOR Trial.

Radiomic Analysis to Predict Outcome in Recurrent Glioblastoma Based on Multi-Center MR Imaging From the Prospective DIRECTOR Trial.

Journal: Frontiers in oncology

Published: December 01, 2020

Radiomics Feature Activation Maps as a New Tool for Signature Interpretability.

Radiomics Feature Activation Maps as a New Tool for Signature Interpretability.

Journal: Frontiers in oncology

Published: July 01, 2020

Showing 1-12 of 19

Last Updated: 09/26/2026